SNCA and neoplasm: By perturbing immune inhibitory genes such as PD-1 (Programmed Death-1) and CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4) in T cells, CRISPR can stimulate anti-tumor immune responses, hence enhancing the therapeutic outcomes of immune checkpoint inhibitors (ICIs) in resistant tumors [36].